A report said AstraZeneca is in talks with Bristol Myers Squibb about a potential merger valued at about $400 billion, which would rank among the largest deals in the sector. The Financial Times said discussions are at an early stage and framed the prospect as a potential consolidation move combining two major portfolios. The story is notable for biotech industry professionals because deal-scale changes the bargaining dynamics across big pharma ecosystems—potentially affecting asset divestment, pipeline prioritization, and competitive positioning in oncology and immunology-adjacent markets. No binding agreement was reported, and final terms would depend on regulatory review, shareholder approval, and integration strategy if talks advance. Even without confirmation of a deal, M&A talks at this scale typically shift how investors underwrite near-term pipeline catalysts and manufacturing priorities.